Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY-NC 4.0Journal of Inflammation Research

Epigenetic Regulation of Pyroptosis in Kidney Disease: From Molecular Mechanisms to Therapeutic Potential

  1. 1Pediatric Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, People’s Republic of China
  2. 2School of Pediatric Medicine, Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China
  3. 3School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China

Abstract

Kidney disease is a significant global health burden, driving substantial mortality and years of life lost. As a pro-inflammatory form of programmed cell death (PCD), pyroptosis is characterized by the rupture of the plasma membrane, cell lysis, and the release of intracellular contents. Emerging evidence has implicated pyroptosis as an important contributor to kidney disease pathogenesis, showing that it involves in structural damage and functional impairment in renal cells. Pyroptosis is regulated by genetically encoded intracellular mechanisms, with epigenetic modifications representing a prevalent and critical regulatory modality. Epigenetic regulation involves multiple regulatory layers, including DNA methylation, histone modifications, RNA modifications, and non-coding RNA-mediated regulation. This review explores how multiple epigenetic regulatory mechanisms collectively modulate pyroptosis and its crosstalk with other forms of PCD, highlighting their cell type-specific and context-dependent effects in kidney disease. Preclinical evidence indicates that these regulatory mechanisms modulate pyroptosis in renal tubular epithelial cells, podocytes, glomerular mesangial cells, macrophages, and renal cancer cells. This regulation may influence inflammatory responses, renal fibrosis, and tumor progression, potentially exerting renoprotective and antitumor effects. Building on this, we summarize emerging therapeutic strategies, including epigenetic-targeting drugs, Traditional Chinese Medicine interventions, and exosome-based therapies. These strategies aim to suppress excessive pyroptosis in non-malignant kidney diseases or induce tumor-cell pyroptosis in renal cancer. Future clinical trials are needed to validate these findings and facilitate their clinical translation.

Related

  1. Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
    Zhibo Zhang, Jie Liu, Guofeng Lei +1
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCPMC
  2. Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
    Srinivasa B, Devika P Jeeragyal, Kiran Velukuri +6
    Advanced Pharmaceutical BulletinPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMCEurope PMC
  3. Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.
    Shaocun Zhang, Yu Wang, Xin Min +2
    Signal transduction and targeted therapyPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMC
  4. Unraveling the pyroptosis-mitophagy axis: from molecular mechanisms to therapeutic opportunities
    Jiaqi Ban, Ranxing Chen, Lihong Ao +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCPMC
  5. Exercise-Mediated Regulation of Pyroptosis in Diabetes and Its Complications: Molecular Mechanisms and Translational Perspectives
    Junzhe Li, Ze Wang, Danlin Zhu +2
    BiomoleculesPeer-reviewedCC BY 4.0General biochemistryCrossref
BibTeX
@article{sheng2026epigenetic,
  title = {{Epigenetic Regulation of Pyroptosis in Kidney Disease: From Molecular Mechanisms to Therapeutic Potential}},
  author = {Daoyu Sheng and Shanshan Han and Wenya Shang and Ying Ding},
  journal = {Journal of Inflammation Research},
  year = {2026},
  month = nov,
  doi = {10.2147/jir.s643757},
  url = {https://doi.org/10.2147/jir.s643757},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Epigenetic Regulation of Pyroptosis in Kidney Disease: From Molecular Mechanisms to Therapeutic Potential
AU  - Daoyu Sheng
AU  - Shanshan Han
AU  - Wenya Shang
AU  - Ying Ding
PY  - 2026
DA  - 2026/11/02
JO  - Journal of Inflammation Research
DO  - 10.2147/jir.s643757
UR  - https://doi.org/10.2147/jir.s643757
AB  - Kidney disease is a significant global health burden, driving substantial mortality and years of life lost. As a pro-inflammatory form of programmed cell death (PCD), pyroptosis is characterized by the rupture of the plasma membrane, cell lysis, and the release of intracellular contents. Emerging evidence has implicated pyroptosis as an important contributor to kidney disease pathogenesis, showing that it involves in structural damage and functional impairment in renal cells. Pyroptosis is regulated by genetically encoded intracellular mechanisms, with epigenetic modifications representing a prevalent and critical regulatory modality. Epigenetic regulation involves multiple regulatory layers, including DNA methylation, histone modifications, RNA modifications, and non-coding RNA-mediated regulation. This review explores how multiple epigenetic regulatory mechanisms collectively modulate pyroptosis and its crosstalk with other forms of PCD, highlighting their cell type-specific and context-dependent effects in kidney disease. Preclinical evidence indicates that these regulatory mechanisms modulate pyroptosis in renal tubular epithelial cells, podocytes, glomerular mesangial cells, macrophages, and renal cancer cells. This regulation may influence inflammatory responses, renal fibrosis, and tumor progression, potentially exerting renoprotective and antitumor effects. Building on this, we summarize emerging therapeutic strategies, including epigenetic-targeting drugs, Traditional Chinese Medicine interventions, and exosome-based therapies. These strategies aim to suppress excessive pyroptosis in non-malignant kidney diseases or induce tumor-cell pyroptosis in renal cancer. Future clinical trials are needed to validate these findings and facilitate their clinical translation.
SN  - 1178-7031
ER  -